IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma

References

• Laursen L. A preventable cancer. Nature. 2014;516(7529):S2–S3. doi:10.1038/516S2a25470197
   PubMedGoogle Scholar
• Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol. 2014;20(30):10223–10237. doi:10.3748/wjg.v20.i30.1022325132740
   PubMed Web of Science ®Google Scholar
• Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J Hepatocell Carcinoma. 2017;4:81–92. doi:10.2147/JHC.S10737028721349
   PubMed Web of Science ®Google Scholar
• Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma. 2017;4:93–103. doi:10.2147/JHC.S10652928744453
   PubMed Web of Science ®Google Scholar
• Lu LC, Hsu CH, Hsu C, Cheng AL. Tumor heterogeneity in hepatocellular carcinoma: facing the challenges. Liver Cancer. 2016;5(2):128–138. doi:10.1159/00036775427386431
   PubMed Web of Science ®Google Scholar
• Hansen M, Andersen MH. The role of dendritic cells in cancer. Semin Immunopathol. 2017;39(3):307–316. doi:10.1007/s00281-016-0592-y27638181
   PubMed Web of Science ®Google Scholar
• Santos PM, Butterfield LH. Dendritic cell-based cancer vaccines. J Immunol. 2018;200(2):443–449. doi:10.4049/jimmunol.170102429311386
   PubMed Web of Science ®Google Scholar
• Harimoto H, Shimizu M, Nakagawa Y, et al. Inactivation of tumor-specific CD8(+) CTLs by tumor-infiltrating tolerogenic dendritic cells. Immunol Cell Biol. 2013;91(9):545–555. doi:10.1038/icb.2013.3824018532
   PubMed Web of Science ®Google Scholar
• Wu SD, Ma YS, Fang Y, Liu LL, Fu D, Shen XZ. Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat Rev. 2012;38(3):218–225. doi:10.1016/j.ctrv.2011.06.01021763074
   PubMed Web of Science ®Google Scholar
• Han Y, Chen Z, Yang Y, et al. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology. 2014;59(2):567–579. doi:10.1002/hep.2669423960017
   PubMed Web of Science ®Google Scholar
• Kakumu S, Ito S, Ishikawa T, et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol. 2000;15(4):431–436.10824889
   PubMed Web of Science ®Google Scholar
• Chen S, Akbar SM, Tanimoto K, et al. Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. Cancer Lett. 2000;148(1):49–57.10680592
   PubMed Web of Science ®Google Scholar
• Wu B, Meng K, Ji Q, et al. Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice. Clin Exp Immunol. 2014;176(3):438–451. doi:10.1111/cei.1228424527881
   PubMed Web of Science ®Google Scholar
• Gao W, Kumar S, Lotze MT, Hanning C, Robbins PD, Gambotto A. Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J Immunol. 2003;170(1):107–113. doi:10.4049/jimmunol.170.1.10712496389
   PubMed Web of Science ®Google Scholar
• Ge G, Wang A, Yang J, et al. Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer. J Exp Clin Cancer Res. 2016;35:13. doi:10.1186/s13046-016-0444-626791086
   PubMed Web of Science ®Google Scholar
• Yan X, Zhao J, Zhang R. Interleukin-37 mediates the antitumor activity in colon cancer through beta-catenin suppression. Oncotarget. 2017;8(30):49064–49075. doi:10.18632/oncotarget.1709328467774
   PubMedGoogle Scholar
• Wang S, An W, Yao Y, et al. Interleukin 37 expression inhibits STAT3 to suppress the proliferation and invasion of human cervical cancer cells. J Cancer. 2015;6(10):962–969. doi:10.7150/jca.1226626316892
   PubMed Web of Science ®Google Scholar
• Wang WQ, Zhao D, Zhou YS, et al. Transfer of the IL-37b gene elicits anti-tumor responses in mice bearing 4T1 breast cancer. Acta Pharmacol Sin. 2015;36(4):528–534. doi:10.1038/aps.2015.325832432
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Pan QZ, Pan K, et al. Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells. Sci Rep. 2014;4:5177. doi:10.1038/srep0517724898887
   PubMed Web of Science ®Google Scholar
• He S, Wang L, Wu Y, Li D, Zhang Y. CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo. J Exp Clin Cancer Res. 2010;29:37. doi:10.1186/1756-9966-29-1720420712
   PubMed Web of Science ®Google Scholar
• Holcmann M, Drobits B, Sibilia M. How imiquimod licenses plasmacytoid dendritic cells to kill tumors. Oncoimmunology. 2012;1(9):1661–1663. doi:10.4161/onci.2203323264929
   PubMed Web of Science ®Google Scholar
• Kalinski P. Dendritic cells in immunotherapy of established cancer: roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs. 2009;10(6):526–535.
   PubMedGoogle Scholar
• Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000;1(4):311–316. doi:10.1038/7975811017102
   PubMed Web of Science ®Google Scholar
• Berk E, Kalinski P. Lymphocyte-polarized DC1s: effective inducers of tumor-specific CTLs. Oncoimmunology. 2012;1(8):1443–1444. doi:10.4161/onci.2129523243623
   PubMed Web of Science ®Google Scholar
• de Jong EC, Smits HH, Kapsenberg ML. Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol. 2005;26(3):289–307. doi:10.1007/s00281-004-0167-115609003
   PubMed Web of Science ®Google Scholar
• Salcedo R, Hixon JA, Stauffer JK, et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol. 2009;182(7):4328–4338. doi:10.4049/jimmunol.080047119299733
   PubMed Web of Science ®Google Scholar
• Medrano RFV, Hunger A, Mendonca SA, Barbuto JAM, Strauss BE. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget. 2017;8(41):71249–71284. doi:10.18632/oncotarget.1953129050360
   PubMedGoogle Scholar
• Ma Y, Shurin GV, Gutkin DW, Shurin MR. Tumor associated regulatory dendritic cells. Semin Cancer Biol. 2012;22(4):298–306. doi:10.1016/j.semcancer.2012.02.01022414911
   PubMed Web of Science ®Google Scholar
• McCormack R, de Armas L, Shiratsuchi M, Podack ER. Killing machines: three pore-forming proteins of the immune system. Immunol Res. 2013;57(1–3):268–278. doi:10.1007/s12026-013-8469-924293008
   PubMed Web of Science ®Google Scholar
• Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2011;21(1):35–43. doi:10.1016/j.semcancer.2010.10.00720946957
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16(3):183–194. doi:10.1016/j.ccr.2009.06.01719732719
   PubMed Web of Science ®Google Scholar
• Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol. 2015;194(7):2985–2991. doi:10.4049/jimmunol.140313425795789
   PubMed Web of Science ®Google Scholar
• Strioga M, Schijns V, Powell DJ Jr., Pasukoniene V, Dobrovolskiene N, Michalek J. Dendritic cells and their role in tumor immunosurveillance. Innate Immun. 2013;19(1):98–111. doi:10.1177/175342591244954922732734
   PubMed Web of Science ®Google Scholar
• Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449(7161):419–426. doi:10.1038/nature0617517898760
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685–711. doi:10.1146/annurev.immunol.21.120601.14104012615891
   PubMed Web of Science ®Google Scholar
• Ormandy LA, Farber A, Cantz T, et al. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol. 2006;12(20):3275–3282. doi:10.3748/wjg.v12.i20.327516718852
   PubMed Web of Science ®Google Scholar
• Vogt A, Sievers E, Lukacs-Kornek V, et al. Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo. Liver Int. 2014;34(3):447–461. doi:10.1111/liv.1228423998316
   PubMed Web of Science ®Google Scholar
• Yu X, Xia W, Zhang T, et al. Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells. Int J Hematol. 2010;92(2):276–282. doi:10.1007/s12185-010-0654-120697855
   PubMed Web of Science ®Google Scholar
• Cao DY, Yang JY, Dou KF, Ma LY, Teng ZH. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro. Hum Immunol. 2007;68(5):334–341. doi:10.1016/j.humimm.2007.01.00817462500
   PubMed Web of Science ®Google Scholar
• Cai XY, Gao Q, Qiu SJ, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132(5):293–301. doi:10.1007/s00432-006-0075-y16421755
   PubMed Web of Science ®Google Scholar
• Luo Y, Cai X, Liu S, et al. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci U S A. 2014;111(42):15178–15183. doi:10.1073/pnas.141671411125294929
   PubMed Web of Science ®Google Scholar